Find Reports

Select Report Type

Reimbursement Review

Displaying 251 - 275 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
cemiplimab	Libtayo	cemiplimab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Basal cell carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 19, 2021	Mar 4, 2022	PC0260-000
ravulizumab	Ultomiris	ravulizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Paroxysmal nocturnal hemoglobinuria	Reimburse with clinical criteria and/or conditions	Complete	Jul 22, 2021	Feb 11, 2022	SR0700-000
estradiol and progesterone	Bijuva	estradiol and progesterone	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Vasomotor symptoms associated with menopause	Reimburse with clinical criteria and/or conditions	Complete	Jun 30, 2021	Feb 10, 2022	SR0697-000
trientine hydrochloride	Waymade-Trientine	trientine hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Wilson's Disease	Reimburse with clinical criteria and/or conditions	Complete	Jul 21, 2021	Feb 8, 2022	SR0696-000
inclisiran	Leqvio	inclisiran	Response to the Procedural Review Panel’s Memorandum Report on the Procedural R…Memorandum report to CADTH Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Primary hypercholesterolemia	Do not reimburse	Complete	Mar 17, 2021	Feb 7, 2022	SR0681-000
Adult Classical Hodgkin Lympho...			Final Report	Adult Classical Hodgkin Lymphoma		Complete		Feb 2, 2022	PH0007-000
isatuximab	Sarclisa	isatuximab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Jul 15, 2021	Jan 28, 2022	PC0256-000
daratumumab	Darzalex	daratumumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Light chain (AL) amyloidosis	Reimburse with clinical criteria and/or conditions	Complete	Jul 15, 2021	Jan 28, 2022	PC0257-000
sacituzumab govitecan	Trodelvy	sacituzumab govitecan	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions	Locally advanced or metastatic triple-negative breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Jun 30, 2021	Jan 27, 2022	PC0254-000
nivolumab	Opdivo	nivolumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report	Esophageal or gastroesophageal junction cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 7, 2021	Jan 26, 2022	PC0253-000
alpelisib	Piqray	alpelisib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Advanced or Metastatic Breast Cancer	Do not reimburse	Complete	Apr 21, 2021	Jan 26, 2022	PC0247-000
pertuzumab	Perjeta	pertuzumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Early stage breast cancer	Do not reimburse	Complete	Apr 14, 2021	Jan 25, 2022	PC0241-000
mecasermin	Increlex	mecasermin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Severe primary insulin-like growth factor-1 deficiency	Reimburse with clinical criteria and/or conditions	Complete	Jun 14, 2021	Jan 21, 2022	SR0692-000
triheptanoin	Dojolvi	triheptanoin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Long-chain fatty acid oxidation disorders	Reimburse with clinical criteria and/or conditions	Complete	Mar 31, 2021	Jan 21, 2022	SR0684-000
estradiol	Imvexxy	estradiol	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Dyspareunia	Reimburse with clinical criteria and/or conditions	Complete	Jun 23, 2021	Jan 20, 2022	SR0694-000
osimertinib	Tagrisso	osimertinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 24, 2021	Jan 10, 2022	PC0246-000
enfortumab vedotin	Padcev	enfortumab vedotin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Locally advanced or metastatic urothelial carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Jun 23, 2021	Jan 6, 2022	PC0251-000
zanubrutinib	Brukinsa	zanubrutinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Waldenström’s macroglobulinemia	Reimburse with clinical criteria and/or conditions	Complete	May 21, 2021	Dec 21, 2021	PC0248-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Esophageal carcinoma, gastroesophageal junction adenocarcinoma	Reimburse with clinical criteria and/or conditions	Complete	May 26, 2021	Dec 20, 2021	PC0250-000
galcanezumab	Emgality	galcanezumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Prevention of migraine	Reimburse with clinical criteria and/or conditions	Complete	Jun 3, 2021	Dec 15, 2021	SR0693-000
macitentan and tadalafil	Opsynvi	macitentan and tadalafil	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Pulmonary arterial hypertension	Reimburse with clinical criteria and/or conditions	Complete	May 20, 2021	Dec 14, 2021	SR0690-000
luspatercept	Reblozyl	luspatercept	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Myelodysplastic syndromes-associated anemia	Reimburse with clinical criteria and/or conditions	Complete	Jan 28, 2021	Dec 7, 2021	SR0670-000
chlormethine hydrochloride	Ledaga	chlormethine hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	T-cell lymphoma	Do not reimburse	Complete	Dec 21, 2020	Nov 24, 2021	PC0242-000
tucatinib	Tukysa	tucatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Advanced or Metastatic Breast Cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 26, 2021	Nov 17, 2021	PC0243-000
idecabtagene vicleucel	Abecma	idecabtagene vicleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, and Ethics combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Multiple myeloma	Do not reimburse	Complete	Dec 16, 2020	Nov 12, 2021	PG0240-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 251 - 275 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Liposuction for Lipedema: A 2022 Update	Liposuction for Lipedema: 2022 Update	Aug 12, 2022	Rapid Review	Completed	RC1447-000
Mesalamine for the Treatment of Crohn Disease	Mesalamine for the Treatment of Crohn’s Disease	Aug 10, 2022	Rapid Review	Completed	RC1445-000
Post-COVID-19 Condition: A summary of existing guidelines	Post-COVID-19 Condition: A summary of existing guidelines	Aug 4, 2022	Technology Review	Complete	HC0037-000
Portable Bone Imaging Devices for Screening and Diagnosing Osteoporosis	Portable Bone Imaging Devices for Screening and Diagnosing Osteoporosis	Aug 2, 2022	Rapid Review	Completed	RC1438-000
Models of Care for People Re-Entering the Community After Incarceration	Models of Care for People Re-Entering the Community After Incarceration	Aug 2, 2022	Technology Review	Completed	HC0039-000
Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma	Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Trea…	Aug 2, 2022	Rapid Review	Completed	RC1441-000
Interventions for the treatment of obstructive sleep apnea: economic update		Jul 29, 2022	Technology Review	In Progress	HE0038-000
Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder	Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disord…	Jul 27, 2022	Rapid Review	Completed	RC1440-000
Multiple Prosthetic Sockets for Lower Limb Amputations	Multiple Prosthetic Sockets for Lower Limb Amputations	Jul 21, 2022	Rapid Review	Completed	RC1439-000
Improving Access to Primary Care in Canada	Improving Access to Primary Care in Canada	Jul 19, 2022	Environmental Scan	Completed	ES0363-000
Diacetylmorphine for Adults With Opioid Dependence	Diacetylmorphine for Adults With Opioid Dependence	Jul 18, 2022	Rapid Review	Completed	RC1437-000
Vandetanib for Medullary Thyroid Cancer	Vandetanib for Medullary Thyroid Cancer	Jul 13, 2022	Technology Review	Completed	HD0009-000
Tecovirimat for the Treatment of Human Monkeypox	HC0040-Tecovirimat-(Tpoxx)-Update-sep28.pdf HC0040-Tecovirimat-Drug-Implementation-Advice-Report.pdf	Jul 12, 2022	Technology Review	Completed	HC0040-000
Syphilis Screening for Adolescents and Adults	Syphilis Screening for Adolescents and Adults	Jul 12, 2022	Rapid Review	Completed	RC1434-000
Surveillance Colonoscopy Following Surgery for Colon Cancer	Surveillance Colonoscopy Following Surgery for Colon Cancer	Jul 7, 2022	Summary of Abstracts	Completed	RB1623-000
Intermittently Scanned and Real-Time Continuous Glucose Monitoring for People With Diabetes	Intermittently Scanned and Real-Time Continuous Glucose Monitoring for People W…	Jul 6, 2022	Rapid Review	Completed	RC1436-000
Infliximab for Graft versus Host Disease	Infliximab for Graft versus Host Disease	Jul 6, 2022	Summary of Abstracts	Completed	RB1621-000
Assessment of Postoperative Vital Signs Frequency	Assessment of Postoperative Vital Signs Frequency	Jun 27, 2022	Summary of Abstracts	Completed	RB1620-000
Removable Rigid Dressings for the Post-Operative Management of Leg Amputations	Removable Rigid Dressings for the Post-Operative Management of Leg Amputations	Jun 27, 2022	Summary with Critical Appraisal	Completed	RC1432-000
Private IV Infusion Clinics in Canada	Private IV Infusion Clinics in Canada	Jun 24, 2022	Environmental Scan	Completed	ES0365-000
Intranasal Glucagon for the Treatment of Hypoglycemia	Intranasal Glucagon for the Treatment of Hypoglycemia	Jun 24, 2022	Summary with Critical Appraisal	Completed	RC1435-000
Ibrutinib for Chronic Graft versus Host Disease	Ibrutinib for Chronic Graft versus Host Disease	Jun 24, 2022	Summary with Critical Appraisal	Completed	RC1433-000
Formulary Management of Targeted Immune Modulators for Ulcerative Colitis		Jun 24, 2022	Technology Review	In Progress	HD0010-000
Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer	HT0029 - HTA - Clinical Review Report v8.1.pdf stereotactic_ablative_radiotherapy_for_the_treatment_of_oligometastatic_cancer_v1.pdf HT0029 LSR version history - update 4 v1.4_ref check.pdf ht0029-SABR-in-brief-e.pdf ht0029-sabr-for-oligometastatic-cancer-clinical-protocol.pdf ht0029-sabr-for-oligometastatic-cancer-scoping-brief.pdf	Jun 21, 2022		Completed	HT0029-000/HT0029-004
Utilization of Cholinesterase Inhibitors for Alzheimer’s Disease in Canada	Utilization of Cholinesterase Inhibitors for Alzheimer’s Disease in Canada	Jun 13, 2022	Technology Review	Completed	HC0027-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 251 - 275 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Emerging Antiviral Drugs to Prevent or Treat Influenza	Emerging Antiviral Drugs to Prevent or Treat Influenza	Dec 16, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH0128-000
belumosudil	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 13, 2024	Reimbursement Review		Complete	SR0789-000
Philadelphia negative acute lymphoblastic leukemia	Proposed Scope	Dec 12, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0067-000
Non-small-cell lung cancer	Proposed Scope Proposed Scope # PH0059-000	Dec 12, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0065-000
vutrisiran	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0801-000
somapacitan	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0779-000
dupilumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0774-000
roflumilast	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0771-000
cenobamate	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0770-000
setmelanotide	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0769-000
evolocumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Dec 11, 2024	Reimbursement Review		Complete	SR0821-000
HR positive, HER2 negative breast cancer	Final Report	Dec 10, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0053-000
etrasimod	Recommendation and Reason Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Dec 9, 2024	Reimbursement Review		Complete	SR0795-000
naloxagol	Proposed Scope	Dec 9, 2024	Reimbursement Review		Active	SX0753-000
Use of Oral Fluoroquinolones in Canada: Drug Utilization Study Update	Report Protocol Summary Report	Dec 6, 2024	Health Technology Review	Technology Review	Complete	HC0073-000
Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation	Final Report	Dec 5, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0054-000
Artificial Intelligence–Assisted Colonoscopy for Detecting Polyps, Adenomas, Precancerous Lesions, and Colorectal Cancer	Artificial Intelligence–Assisted Colonoscopy for Detecting Polyps, Adenomas, Pr…	Dec 5, 2024	Health Technology Review	Rapid Review	Completed	RC1559-000
RapidAI for Stroke Detection	Final Recommendation RapidAI for Stroke Detection: Main Report Supporting Information for RapidAI Review Supporting Information for AI Implementation Review	Dec 5, 2024	Health Technology Review	Optimal Use	Active	OP0556-000
Advanced or metastatic gastric, gastroesophageal junction, or esophageal cancer	Final Report	Dec 3, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0051-000
Attention-Deficit/Hyperactivity Disorder Medications for Adults	Attention-Deficit/Hyperactivity Disorder Medications for Adults	Dec 3, 2024	Health Technology Review	Rapid Review	Completed	RC1556-000
Pharmaceutical Reviews Update — Issue 53		Nov 28, 2024	Reimbursement Review	Pharmaceutical Review Update
Esophageal or Gastroesophageal Junction Cancer	Proposed Scope	Nov 28, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0061-000
Overview of Systematic Reviews of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer with EGFR, ALK, ROS1, and RET Actionable Driver Mutations	Summary Report Final Report Protocol - Final	Nov 26, 2024	Health Technology Review	Systematic Review	Completed	RE0050-000
Utilization of Cancer Therapies for Advanced Non–Small Cell Lung Cancer With an Oncogenic Driver Mutation	Summary Report Utilization of Cancer Therapies for Advanced Non–Small Cell Lung Cancer With an…Final Project Protocol	Nov 26, 2024	Health Technology Review	Technology Review	Completed	HC0084-OS0008
remdesivir	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input Stakeholder feedback on Draft Recommendation	Nov 26, 2024	Reimbursement Review		Complete	SR0834-000